Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome

Abstract

After a standard dose of IVIg treatment, GBS patients show a large variation in pharmacokinetics, which is related to clinical outcome. This may indicate that patients with a small increase in serum IgG level may benefit from a higher dosage or second course of IVIg.